OOIR: Observatory of International Research

Papers

(The median citation count of Pharmacological Reviews is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies	428
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels	282
Is Oxytocin “Nature’s Medicine”?	215
RNA Drugs and RNA Targets for Small Molecules: Principles, Progress, and Challenges	208
Rescuing the Last-Line Polymyxins: Achievements and Challenges	190
Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development	171
Subcellular Organization of the cAMP Signaling Pathway	157
International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function	148
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials	134
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms	118
Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology	109
Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics	102
Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950	94
Sex- and Gender-Based Pharmacological Response to Drugs	93
Post-Translational Modifications of G Protein–Coupled Receptors Control Cellular Signaling Dynamics in Space and Time	92
International Union of Basic and Clinical Pharmacology. CXII: Adenosine Receptors: A Further Update	77
On the Clinical Pharmacology of Reactive Oxygen Species	75
Structure-Based Virtual Screening for Ligands of G Protein–Coupled Receptors: What Can Molecular Docking Do for You?	73
Sex Differences in Opioid and Psychostimulant Craving and Relapse: A Critical Review	73
Mutations in G Protein–Coupled Receptors: Mechanisms, Pathophysiology and Potential Therapeutic Approaches	71
Dopamine, Immunity, and Disease	71
Unlocking G-Quadruplexes as Antiviral Targets	67
Animal Models of Drug Relapse and Craving after Voluntary Abstinence: A Review	65
Aldo-Keto Reductases and Cancer Drug Resistance	64
Ontogeny of Hepatic Transporters and Drug-Metabolizing Enzymes in Humans and in Nonclinical Species	64

Sex Differences in the Epilepsies and Associated Comorbidities: Implications for Use and Development of Pharmacotherapies	63
E1 Enzymes as Therapeutic Targets in Cancer	62
Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications	59
Inhaled Medicines: Past, Present, and Future	52
ATP and Adenosine Metabolism in Cancer: Exploitation for Therapeutic Gain	44
Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning	43
Neurobiological Mechanisms of Nicotine Reward and Aversion	42
Therapeutic Targeting of α7 Nicotinic Acetylcholine Receptors	42
Therapeutics in the Pipeline Targetingα-Synuclein for Parkinson's Disease	41
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications	41
Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development	40
The Molecular Biology of Phosphodiesterase 4 Enzymes as Pharmacological Targets: An Interplay of Isoforms, Conformational States, and Inhibitors	39
Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain	38
Cathepsin B Gene Knockout Improves Behavioral Deficits and Reduces Pathology in Models of Neurologic Disorders	37
The Angiotensin AT₂Receptor: From a Binding Site to a Novel Therapeutic Target	37
Post-Traumatic Epilepsy and Comorbidities: Advanced Models, Molecular Mechanisms, Biomarkers, and Novel Therapeutic Interventions	36
International Union of Basic and Clinical Pharmacology. CXI. Pharmacology, Signaling, and Physiology of Metabotropic Glutamate Receptors	36
Gαs–Protein Kinase A (PKA) Pathway Signalopathies: The Emerging Genetic Landscape and Therapeutic Potential of Human Diseases Driven by Aberrant Gαs-PKA Signaling	35
The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein	35
Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction	32
Sex/Gender Differences in the Time-Course for the Development of Substance Use Disorder: A Focus on the Telescoping Effect	31
Development of Novel, Value-Based, Digital Endpoints for Clinical Trials: A Structured Approach Toward Fit-for-Purpose Validation	30
International Union of Basic and Clinical Pharmacology. CIX. Differences and Similarities between Human and Rodent Prostaglandin E₂Receptors (EP1–4) and Prostacyclin Receptor (IP): Specific	29
Extracellular Vesicle Heterogeneity and Its Impact for Regenerative Medicine Applications	28
Pharmacological Targeting of Mitochondria in Diabetic Kidney Disease	27
Evidence for Modulation of Substance Use Disorders by the Gut Microbiome: Hidden in Plain Sight	27
Targeting the Adaptive Immune System in Depression: Focus on T Helper 17 Cells	27
Analgesic Potential of Terpenes Derived fromCannabis sativa	27
Cognitive Impairment in Older Adults and Therapeutic Strategies	26
Targeting Systemic Innate Immune Cells as a Therapeutic Avenue for Alzheimer Disease	26
Neural Mechanisms and Psychology of Psychedelic Ego Dissolution	26
Organotypic and Microphysiological Human Tissue Models for Drug Discovery and Development—Current State-of-the-Art and Future Perspectives	25
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years	25
Carbon Monoxide Signaling: Examining Its Engagement with Various Molecular Targets in the Context of Binding Affinity, Concentration, and Biologic Response	24
β−Arrestins: Structure, Function, Physiology, and Pharmacological Perspectives	24
The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions	23
Pharmacogenomics: Driving Personalized Medicine	22
Pharmacology of Heparin and Related Drugs: An Update	22
Understanding the Neural Mechanisms of General Anesthesia from Interaction with Sleep–Wake State: A Decade of Discovery	22
Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review	21
The Nitrogen Mustards	20
Kidney Angiotensin in Cardiovascular Disease: Formation and Drug Targeting	20
Current and Emerging Pharmacological Targets and Treatments of Urinary Incontinence and Related Disorders	19
Elucidating the Interactome of G Protein-Coupled Receptors and Receptor Activity-Modifying Proteins	17
Cellular Senescence: From Mechanisms to Current Biomarkers and Senotherapies	17
New Technologies Bloom Together for Bettering Cancer Drug Conjugates	16
α6-Containing GABA_AReceptors: Functional Roles and Therapeutic Potentials	16
Viral G Protein–Coupled Receptors: Attractive Targets for Herpesvirus-Associated Diseases	15
Parkinson Disease: Translating Insights from Molecular Mechanisms to Neuroprotection	15
Allosteric Modulators of Metabotropic Glutamate Receptors as Novel Therapeutics for Neuropsychiatric Disease	15

Potassium Channels in Parkinson’s Disease: Potential Roles in Its Pathogenesis and Innovative Molecular Targets for Treatment	15
Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential	14
L-Type Calcium Channel Blockers: A Potential Novel Therapeutic Approach to Drug Dependence	14
Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy	14
Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies	14